Alphamab Oncology receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alphamab Oncology (9966)
Alphamab Oncology stock price live, this page displays HK 9966 stock exchange data. View the 9966 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Alphamab Oncology real time stock price chart below.
What Is the Alphamab Oncology Stock Price Today?
The Alphamab Oncology stock price today is 6.90.
What Is the Stock Symbol for Alphamab Oncology?
The stock symbol for Alphamab Oncology is "9966."
What Stock Exchange Does Alphamab Oncology Trade On?
Alphamab Oncology is listed and trades on the Hong Kong stock exchange.
Is Alphamab Oncology a Good Stock to Buy?
Determining whether Alphamab Oncology—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 9966 quote. (ISIN: KYG0330A1013)
What Is the Alphamab Oncology Stock Price Today?
The Alphamab Oncology stock price today is 6.90.
What Is the Stock Symbol for Alphamab Oncology?
The stock symbol for Alphamab Oncology is "9966."
What Stock Exchange Does Alphamab Oncology Trade On?
Alphamab Oncology is listed and trades on the Hong Kong stock exchange.
Is Alphamab Oncology a Good Stock to Buy?
Determining whether Alphamab Oncology—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 9966 quote. (ISIN: KYG0330A1013)
Hong Kong
Currency in HKD
6.90
+0.23(+3.45%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.81
7.18
52 wk Range
6.23
15.30
9966 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.817.18
52 wk Range
6.2315.30
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
9966 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
9.95
Upside
+44.21%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Alphamab Oncology receives Investment Bank Analyst Rating Update- Investing.com
Pro
Alphamab Oncology receives Investment Bank Analyst Rating Update- Investing.com
Pro
NIO (H-Shares) receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Alphamab Oncology receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Alphamab Oncology receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Alphamab Oncology receives Investment Bank Analyst Rating Update
- Investing.com
Pro - NIO (H-Shares) receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Neutral
Moving Averages
Strong Sell
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 9.95
(+44.21% Upside)
Earnings
Latest Release
Aug 27, 2026
EPS / Forecast
-0.04 / --
Revenue / Forecast
271.24M / --
Compare 9966 to Peers and Sector
Metrics to compare | 9966 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship9966PeersSector | |
|---|---|---|---|---|
P/E Ratio | −32.4x | −11.8x | −0.3x | |
PEG Ratio | 0.18 | −0.23 | 0.00 | |
Price/Book | 3.4x | 4.0x | 2.6x | |
Price / LTM Sales | 11.0x | 15.6x | 2.9x | |
Upside (Analyst Target) | 44.1% | 54.7% | 67.1% | |
Fair Value Upside | Unlock | −2.2% | 9.9% | Unlock |
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) that is in Phase III clinical trials to treat HER2-positive breast cancer and HER2-positive gastric cancer or gastroesophageal junction cancer; KN046, a BsAb immune checkpoint inhibitor in Phase III clinical trial for the treatment of non-small cell lung cancer (NSCLC), squamous NSCLC, triple-negative breast cancer, and recurrent and metastatic esophageal squamous cell carcinoma; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC) that is in Phase III clinical trial to treat HER2-expressing advanced or metastatic solid tumors, HER2-low expression breast cancer, platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. In addition, the company is developing JSKN016, a bispecific ADC that is in Phase II clinical trial for the treatment of solid tumors, lung cancer, and breast cancer; JSKN022, a bispecific single-domain antibody; JSKN027, a bispecific ADC that is Phase I clinical trial; JSKN021; KN019; and JSKN033, a subcutaneous ADC in Phase I clinical trial to treat HER2-expressing advanced or metastatic solid tumors. The company also develops JSKN029, a pre-clinical stage product for oncology applications. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People’s Republic of China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Alphamab (9966) Stock Price Today?
The Alphamab stock price today is 6.90 HKD.
What Stock Exchange Does Alphamab Trade On?
Alphamab is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for Alphamab?
The stock symbol for Alphamab is "9966."
What Is the Alphamab Market Cap?
As of today, Alphamab market cap is 6.68B HKD.
What Is Alphamab's Earnings Per Share (TTM)?
The Alphamab EPS (TTM) is -0.21.
From a Technical Analysis Perspective, Is 9966 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Alphamab Stock Split?
Alphamab has split 0 times.
How Many Employees Does Alphamab Have?
Alphamab has 515 employees.
What is the current trading status of Alphamab (9966)?
As of Oct 18, 2026, Alphamab (9966) is trading at a price of 6.90 HKD, with a previous close of 6.90 HKD. The stock has fluctuated within a day range of 6.81 HKD to 7.18 HKD, while its 52-week range spans from 6.23 HKD to 15.30 HKD.
What Is Alphamab (9966) Price Target According to Analysts?
The average 12-month price target for Alphamab is 9.95 HKD, with a high estimate of 9.95070423 HKD and a low estimate of 9.95070423 HKD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +44.21% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.